Navigation Links
DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC

. In extremely minute quantities, botulinum toxin can be used therapeutically, as for the cosmetic use of Botox®, a commercial preparation of serotype A botulinum toxin, but the effects of the neurotoxin are extremely long lasting and paralytic at higher than therapeutic doses.

About Botulinum Toxin Vaccines

Vaccination is considered the best option to prevent neurological effects of toxin exposure. Because of the rarity of the natural disease, a vaccine would not be used in mass population immunization programs unless they were actually used or a significant threat. In that event, the vaccine would have to be made available for widespread dissemination for rapid and convenient vaccination of a large population. The only vaccine available is an experimental vaccine based on inactivation of a mixture of serotypes of the natural toxins that is given by injection, is not licensed by the FDA and cannot be used for widespread immunization. New multivalent vaccines based on non-toxic subunits are being developed, including BT-VACC™.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal ("GI") diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI graft-versus-host disease ("GVHD"), a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA with the FDA for the treatment of GI GVHD, and has received a PDUFA date of July 21, 2007. An MAA with the EMEA for orBec® has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has also recently initiated a clinical development program with its Lipid Polymer Micelle
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ... from Hercules Technology Growth Capital, Inc. (NYSE: ... final advance under the Loan and Security Agreement that ... , Alimera Sciences Limited, entered into with Hercules in ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... Planet Biopharmaceuticals, Inc. and its wholly owned Subsidiaries ... on providing products for allergy and asthma sufferers, today ... ALLERGY CONTROL PRODUCTS, INC., a Delaware corporation("ACP") to RH ... Theron E. Odlaug, Ph. D., CEO and ...
... Communication efforts on behalf of the public and private healthcare ... are today, according to a new book , "Health ... Nancy J. Hicks and Christina Mazzola Nicols of Ketchum ... The book, released this fall from Jones & ...
Cached Medicine Technology:New Book Highlights Opportunities for Healthcare Industry Communications 2New Book Highlights Opportunities for Healthcare Industry Communications 3New Book Highlights Opportunities for Healthcare Industry Communications 4New Book Highlights Opportunities for Healthcare Industry Communications 5
(Date:10/1/2014)... (PRWEB) October 01, 2014 Familylifeinsurancequotes.org ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
(Date:10/1/2014)... Join the more than 80 golfers who already have ... charity golf tournament to benefit Project HEAL, a not-for-profit organization ... afford treatment. The tournament will be held Monday, Oct. 6, ... The day-long event starts with 10:30 a.m. check-in and shotgun ... begin at 5 p.m. and will include an auction featuring ...
(Date:10/1/2014)... Kennebunkport, Maine (PRWEB) October 01, 2014 ... autoimmune disorders in the U.S., according to figures from ... Autoimmune Related Diseases Association (AARDA), and many of them ... higher chance of having undiagnosed celiac disease. Gluten ... helping raise awareness of undiagnosed celiac disease by publishing ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... have to drink more to feel drunk than non-smoking ... their brains, livers and hearts, a new study suggests. ... rats, which are considered a good model for humans.Since alcohol ... more alcohol to get an expected level of intoxication, say ...
... study of the similarities and differences in disease patterns in ... We share many of our genes with our primate cousins ... similar in many ways, but dogs do not suffer from ... ,Professor Bob Michell is Professor of Comparative Medicine at ...
... a lot of drug-company money to tell doctors not to ... makes sense to involve the industry in a campaign that's ... unethical behavior. // ,At issue are the ... and trips, that some drug makers shower on doctors. Ethicists ...
... your genes, and everything to do with your upbringing say UK ... believed to be at least partly genetically determined - so researchers ... team asked 71 pairs of identical twins and 56 pairs of ... on a scale of 0 to 10.// A zero deemed the ...
... genome sequence suggests a route to new antibiotics, and ... even minor infections can become a major threat. There ... resistant bacteria.// ,Antibiotic resistance is a growing public ... from the soil bacteria Streptomyces , including erthyromycin and ...
... the Study of Aging and the International Longevity Center says ... advised to put down the pill bottle and pick up ... crossword puzzles, exercise and seek help for emotional problems may ... unproven cures such as melatonin, DHEA, testosterone and human growth ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: